Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancer

Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancer

Background Neoadjuvant anti-programmed cell death protein-1 (PD-1) therapy exhibits potential in treating resectable non-small cell lung cancer (NSCLC). Previously, we have reported the 3-year clinical outcomes of this trial, implying the effectiveness and feasibility of neoadjuvant sintilimab monot...

Full description

Bibliographic Details
Main Authors: Ning Li, Jian Li, Liang Zhao, Fan Zhang, Wei Guo, Shugeng Gao, Shuhang Wang, Fang Lv, Kang Shao, Qi Xue, Bin Qiu, Bolun Zhou
Format: Article
Language:English
Published: BMJ Publishing Group 2024-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/8/e009355.full

Internet

https://jitc.bmj.com/content/12/8/e009355.full

Similar Items